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Abstract 
Background: Quality indicators (QIs) are tools to improve the delivery of evidence-base 
medicine. In 2017, the European Society of Cardiology (ESC) Association for Acute 
Cardiovascular Care (ACVC) developed a set of QIs for acute myocardial infarction (AMI), 
which have been evaluated at national and international levels and across different 
populations. However, an update of these QIs is needed in light of the accumulated 
experience and the changes in the supporting evidence.  
Scope: The ESC methodology for the QI development was used to update the 2017 ACVC 
QIs. We identified key domains of AMI care, conducted a literature review, developed a list 
of candidate QIs, and used a modified Delphi method to select the final set of indicators.  
Indicators: The same seven domains of AMI care identified by the 2017 Study Group were 
retained for this update. For each domain, main and secondary QIs were developed reflecting 
the essential and complementary aspects of care, respectively. Overall, 26 QIs were proposed 
in this document, compared to 20 in the 2017 set. New QIs were proposed in this document 
(e.g., the center use of high-sensitivity troponin), some were retained or modified (e.g., the in-
hospital risk assessment), and others were retired in accordance with the changes in evidence 
(e.g., the proportion of patients with NSTEMI treated with fondaparinux) and the feasibility 
assessments (e.g. the proportion of patients with NSTEMI whom risk assessment is performed 
using the GRACE and CRUSADE risk scores).   
Conclusion: Updated QIs for the management of AMI were developed according to 
contemporary knowledge and accumulated experience. These QIs may be applied to evaluate 
and improve the quality of AMI care. 
Keywords: Quality indicators, quality improvement, myocardial infarction 
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Background  
Assessing the quality of care has become mandatory in many healthcare systems and is an 
intrinsic component of quality improvement. In 2017, the European Society of Cardiology 
(ESC) Association for Acute Cardiovascular Care (ACVC) published a position paper 
defining quality indicators (QIs) for acute myocardial infarction (AMI) [1] with the aim of 
supporting quality improvement, and based on the assumption that rigorous measurement is 
fundamental. This was the first QI initiative undertaken within the ESC by one of its 
constituent associations, concordant with the mission statement of the ACVC to “improve the 
quality of care of patients with acute cardiovascular disease”. The ACVC Study Group on QIs 
(Supplementary Table 1) decided that QIs should not only reflect high-grade 
recommendations in ESC guidelines, but should consider the domains of care for which there 
is potential room for improvement, and where measurement can be performed using existing 
registries or databases. As a result, the ACVC QIs covered 7 domains of care, including 
centre organisation, reperfusion/invasive strategies, risk assessment, antithrombotic selection, 
secondary prevention, and patient experience. Lastly, 2 composite indicators and one outcome 
were defined.  
Objectives 
The 2017 ESC ACVC QIs were used to support quality assessment and improvement at 
national [2-7] and international levels [8], and across different populations [9]. Various 
studies evaluating the ESC ACVC QIs using existing registries, have shown that most QIs can 
be captured, and, thus can guide the development of future cardiovascular registries [10]. In 
addition, the ESC ACVC QIs identified gaps in care delivery within and between countries, 
highlighting missed opportunities to improve clinical outcomes [2, 3, 5, 9].  
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Three years after the publication of the initial set of QIs, the ACVC study group on QI 
considered that an update was timely, because the ESC has updated its Clinical Practice 
Guidelines for the management of patients with AMI (with and without ST-segment 
elevation), and published the methodology by which the ESC QIs should be developed [11]. 
Hence, the QI update was driven by the experience accumulated from assessment of previous 
QIs in existing registries (Online Supplement, Table S1), the ESC methodology for QI 
development [11] as well as other methodologies [12, 13], and to ensure the validity of the 
measurements [14]. 
Methods 
The 2017 ESC ACVC QIs were updated using the RAND/University of California–Los 
Angeles (UCLA) appropriateness method [15, 16], which is recommended by the ESC 
methodology for QI development [11], and combines best scientific evidence with the 
collective judgment of experts using the modified Delphi process [17].  
The 2020 ESC ACVC QIs for AMI 
The 7 domains of AMI care identified by the 2017 Study Group were retained. The list of the 
main and secondary QIs for each domain are presented in Figure 1 and Table S2 (online 
Supplement), with the definitions of numerators and denominators, and the corresponding 
ESC guidelines recommendations.  
Domain 1 : Centre organisation  
 Network organisation  
Clinical relevance: In the setting of acute coronary syndrome (ACS), a network organisation 
has a beneficial impact through the availability of different capacities, such as the use of a 
single telephone emergency number, early identification of ACS, transportation with 
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ambulances with basic or advanced life support capability, direct access to catheterization 
laboratory and delivery of care following written protocols [18]. This organisation facilitates 
the selection of the appropriate reperfusion strategy, and reduces times to reperfusion in ST-
segment elevation myocardial infarction (STEMI) patients [19-21]. Furthermore, local, 
regional or national written protocols can help to reduce delays, reduce variations in the 
quality of care [22] and improve the quality of secondary prevention in post-discharge settings 
[23].  
Specific aspects for selection: Two QIs are related to participation in a regional network: the 
main QI (1) as a measure of network organisation for the management of ACS, including 
written protocols; and the assessment of essential components of effective systems of STEMI 
care [18]. Similar QIs were already included in the 2017 ACVC QI list, are supported by 
class IC recommendations and also feature in the list of QIs in the 2017 STEMI [24] and 
2020 non-ST segment elevation ACS (NSTE-ACS) ESC guidelines [25].  
 Availability of high sensitivity troponin assay  
Clinical relevance: Cardiac troponin (cTn) elevation is a key diagnostic and prognostic 
feature in NSTE-ACS. Only ‘high sensitivity’ cardiac troponin (hs-cTn) assays have 
imprecision of <10% at the 99th percentile of the upper reference limit, and have the ability to 
quantify cTn levels in >50% of apparently healthy individuals. Data have shown that more 
sensitive cardiac troponin assays such as hs-troponin assay increase diagnostic accuracy with 
greater and more rapid ability to “rule-in” or “rule-out” myocardial infarction [26].  
Specific aspects for selection: Main QI (2) relates to the availability of hs-cTn assay 
measured at centre level. The use of hs-cTn over less sensitive assays is recommended by 
guidelines [25]. This QI is also included in the QIs list of the 2020 ESC Guidelines for 
NSTE-ACS [25].  
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 Pre-hospital interpretation of ECG 
Clinical relevance: Timely diagnosis for patients with STEMI is determinant for clinical 
outcomes. The ESC guidelines for STEMI recommend acquiring and interpreting a 12-lead 
ECG as soon as possible following first medical contact (FMC) to facilitate early diagnosis 
and risk stratification [23, 24].  
Specific aspects for selection: Main QI (3) captures the availability of systems of care in 
which STEMI diagnosis can be performed in the pre-hospital settings, with the initiation of 
appropriate treatment pathways.  
 Participation in a regular registry or quality assessment programme  
Clinical relevance: Participation in a registry for quality assessment improves adherence to 
guidelines [27]. Major improvements in hospital performance and mortality rates have been 
reported over short periods of time, narrowing the gap between the quality of care delivered 
between hospitals [28, 29] and the association between the participation in a quality 
programme for timely reperfusion therapy and clinical improvement has been shown [23]. In 
addition, the assessment of reperfusion times for STEMI patients is an important and 
measurable component of STEMI care.  
Specific aspects for selection: The two secondary QIs cover the quality improvement 
programme: participation in a regular registry, and regular monitoring of times to reperfusion. 
These QIs were already included in the 2017 ESC STEMI guidelines [24]. 
 
Domain 2: Invasive strategy  
 Reperfusion for STEMI patients  
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Clinical relevance: Reperfusion therapy should be administered to all eligible patients 
presenting with STEMI. Primary percutaneous coronary intervention (PCI) is the preferred 
option, provided it can be performed expeditiously. Based on considerable evidence, the ESC 
guidelines recommend time targets for reperfusion therapy based on the strategy used and the 
initial healthcare facility for which STEMI patients was admitted. As such, time from STEMI 
diagnosis to wire crossing is recommended to be <60 minutes for patients presenting at a 
primary PCI hospital, whereas it  should be <90 minutes for patients diagnosed either in a 
non-PCI hospital or in the out-of-hospital setting. For patients treated by fibrinolysis, the 
recommended time between STEMI diagnosis and initiation of fibrinolysis is <10 minutes 
[24].  
Specific aspects for selection: Both reperfusion and time to reperfusion have been used as key 
indicators of quality in patients with STEMI in most sets of QIs or performance measures 
(PMs) [1, 30, 31]. Main QI (1) assesses the proportion of patients with STEMI admitted 
within 12 hours of the onset of symptoms and treated with reperfusion (irrespective of the 
timing). Main QI (2) assesses “timely” reperfusion, defined for reperfusion strategy, by 
primary PCI or fibrinolysis [32]. The time targets correspond to those recommended by the 
ESC Guidelines [24]. From a practical viewpoint, the measure of the proportion of patients 
with STEMI reperfused among those eligible has been measured in all publications reporting 
ESC-ACVC QIs assessment and ranged from 57% to 98%.  
 Early invasive strategy in NSTEMI patients 
Clinical relevance: Patients with non-ST segment elevation myocardial infarction (NSTEMI) 
are on the spectrum of high-risk NSTE-ACS and, therefore, eligible for an invasive approach. 
The benefit of a routine over a selective invasive approach has been shown in high-risk 
patients and the timing of the strategy is split into immediate (for patients with very high risk 
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features such as persistent chest pain), early (<24 hours after admission for patients with high 
risk features, including those with diagnosis of NSTEMI) or <72 hours.  
Specific aspects for selection: Main QI (3) measures the use of an early invasive strategy and 
is therefore suitable for use in patients with NSTEMI. Compared with the previous QI list, the 
timing has been set at <24 hours (instead of <72 hours), in line with the ESC Guidelines [25, 
33]. 
The use of radial access 
Clinical relevance: The use of radial access is a new QI in this domain. It is justified by the 
reduction in bleeding and vascular complications achieved with the radial approach [34, 35], 
especially in ACS [36].  
Specific aspects for selection: This new QI is likely to be easy to assess and will be applicable 
in the majority of patients, both STEMI and NSTE-ACS. Supported by ESC Guidelines, the 
‘radial-first strategy’ has been referred to as ‘best practice’ in a position paper from the 
American Heart Association (AHA) [37]. 
 
Domain 3: In-hospital risk assessment 
 Assessment of left ventricular ejection fraction  
Clinical relevance: Left ventricular ejection fraction (LVEF) assessment is important for both 
prognostic and therapeutic reasons.  
Specific aspects for selection: This QI was already in the previous ESC ACVC QIs set.  
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 Assessment of LDL-cholesterol 
Clinical relevance: LDL-cholesterol (LDL-c) is considered a causal factor for atherosclerosis 
[38]. Early and intense reduction of LDL-c as soon as possible after admission has been 
shown to be effective. The utility of LDL-c assessment is therefore not for the prescription of 
statins, but rather to have an initial reference value (called ‘baseline’, i.e. without the effect of 
LDL-C lowering therapy) and to estimate the potential likelihood of reaching the 2019 ESC 
guidelines target [39], with a view to using additional therapies such as the combination with 
ezetimibe [40] or the early (within 4-6 weeks after discharge) introduction of a proprotein 
convertase subtilisin–kexin type 9 (PCSK9) inhibitor [39].  
Specific aspects for selection: This QI is new and applicable in all patients.  
 
 Risk assessment using a validated score 
Clinical relevance: Patient stratification using validated scores is important, both for ischemic 
and haemorrhagic risks. Thus, the use of a validated risk score is recommended by the ESC 
Guidelines (Class IA) for prognosis.  
Specific aspects for selection: In the 2017 ESC ACVC QIs, two specific validated scores were 
included as independent QIs (i.e. the GRACE risk score for ischemic risk, and the CRUSADE 
score for haemorrhagic risk). The Study Group decided to retire the specification of the tool 
used, but to keep the recommendation to perform risk assessment using a validated method.  
 
Domain 4: Antithrombotic treatment during hospitalization 
 Proportion of patients with “adequate P2Y12 inhibition” 
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Clinical relevance: In patients with AMI, dual antiplatelet therapy (DAPT) is recommended 
as soon as possible when ACS is suspected. Among patients eligible for DAPT, the choice 
between clopidogrel, prasugrel and ticagrelor is mainly driven by the results of randomized 
studies comparing clopidogrel to prasugrel [41, 42] and to ticagrelor [43, 44], and the 
bleeding risk. ‘Adequate P2Y12 inhibition’ is defined as the appropriate selection of the P2Y12 
inhibitor in accordance with the 2020 ESC Guidelines: 
- the use of ticagrelor in patients without a contraindication (e.g. previous 
haemorrhagic stroke, high bleeding risk, treatment with fibrinolysis, or concomitant 
use of oral anticoagulation).  
- the use of prasugrel in PCI-treated AMI patients without previous haemorrhagic or 
ischaemic stroke, high bleeding risk (patients ⩾75 years of age and/or with body 
weight < 60 kg), fibrinolysis or oral anticoagulation  
- the use of clopidogrel when there is no indication for prasugrel or ticagrelor.  
Specific aspects for selection: Given the importance of selecting the most appropriate P2Y12 
inhibitor in patients with coronary artery disease (i.e. tailored to the patient’s ischaemic and 
bleeding risks), a Task Force of the ESC and European Association for Cardio-Thoracic 
Surgery published a focused update on DAPT [45], in line with the STEMI and NSTE-ACS 
Guidelines, all supporting the concept of ‘adequate P2Y12 inhibition’. This QI already 
featured in the previous ACVC QIs set, and is included in the list of QIs of the 2020 ESC 
Guidelines for NSTE-ACS. Experience with the assessment of the ACVC QIs shows that this 
QI may be measured from many, but not all, existing registries, depending on the quality of 
the variables recorded (Table S1, online Supplement). 
 Parenteral anticoagulant at (or before) admission  
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Clinical relevance: Parenteral anticoagulation is recommended in AMI from the time of 
diagnosis up to PCI unless otherwise indicated. Different anticoagulant agents (unfractionated 
heparin, enoxaparin, fondaparinux or bivalirudin) may be used in this setting. Parenteral 
anticoa gulation is recommended for all patients, in addition to antiplatelet therapy, at the time 
of diagnosis,. 
Specific aspects for selection: This QI replaces the previous QI relating to fondaparinux 
because the ESC Guidelines no longer express a strong preference for any particular drug. 
 
 Patients discharged on dual antiplatelet therapy 
Clinical relevance: The need for DAPT is a cornerstone of AMI management at the time of 
hospital admission and discharge, unless the patient is deemed to be at high bleeding risk [45].  
Specific aspects for selection: This QI is a complement to main QI (1), with the particular 
interest of being more straightforward, easier to assess, and including the prescription of 
aspirin. Contrary to ‘adequate P2Y12 inhibition’, this QI is reported in all published 
assessments. Notably, patients treated with oral anticoagulation are excluded because several 
alternative strategies are available, including some without aspirin. 
 Mention the duration of dual antiplatelet therapy in the discharge letter  
Clinical relevance: Although the standard duration of DAPT after AMI is 12 months, it must 
be determined according to the patient’s risk and ischemic profile, and may range from 1 to 
48 months [45]. At discharge, a shortening or prolongation of the DAPT duration may be 
proposed according to specific tools, depending on the patient’s characteristics, coronary 
anatomy, the extent of coronary artery disease, or PCI procedure.  
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Specific aspects for selection: Poor quality discharge letters represent a deficit in 
communication between hospital specialists and primary care physicians [46]. The post AMI 
discharge document is a crucial element to ensuring transmission of medical information to 
the corresponding physician or the patient, including the ischemic and haemorragic risk as 
perceived during the acute hospitalisation. Standardization of the discharge document, 
including insights about the type and duration of the anti-thrombotic treatment has been 
highlighted by the recent ESC guidelines [25] and its routine application has been accepted by 
a national group in France [47]. 
 
Domain 5: Secondary prevention discharge treatments  
After AMI, patients remain at very high risk and secondary prevention treatment is crucial for 
reducing mortality and further cardiovascular events. The QIs in this domain cover the 
prescription of 3 therapeutic classes, in addition to the anti-thrombotic treatment. 
 High-intensity statins 
Clinical relevance: Statins are fundamental to the treatment of atherosclerosis. In the setting 
of AMI, high intensity statins are safe and provide better prevention as compared to moderate 
intensity [48], irrespective of admission LDL-c. Despite the body of evidence regarding the 
beneficial effects of lowering LDL-c [38] by statins (alone or in combination with ezetimibe 
or PCSK9 inhibitors), their use in current registries remains sub-optimal and the proportion of 
patients at LDL-c target is low: 32% in men and 23% in women in the EuroAspire V registry 
[49].  
Specific aspects for the selection: This QI was already in the 2017 ESC-ACVC list. 
Experience of assessment suggests that this QI cannot be assessed from some registries, 
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because the type and dose of statins prescribed at discharge were not recorded. In addition, it 
is likely that intolerance to high-intensity statins was also not recorded. In registries reporting 
this QI, the rate of prescription of statins (any intensity) is high, but at high-intensity in only 
about half of the patients [49]. 
 
 Patients with LVEF <40% who are discharged from hospital on angiotensin-converting 
enzyme inhibitors (or angiotensin receptor antagonists if intolerant of ACEI) 
Clinical relevance: Angiotensin-converting enzyme inhibitors (ACEI) improve survival in 
patients with impaired LV systolic function, defined by an LVEF <40%. Initiation of ACEI 
(or angiotensin receptor antagonists [ARBs] in patients intolerant to ACEI) and prescription at 
the time of hospital discharge is beneficial among patients with a LVEF <40%.  
Specific aspects for the selection: This QI was already in the 2017 ESC ACVC list, supported 
by a Class IIA recommendation. In practice, the proportion of patients with LVEF <40% is 
15-20% in current registries; therefore, the QI applies only to a subset of high-risk patients.  
 
 Patients with LVEF <40% who are discharged from hospital on beta-blockers 
Clinical relevance: Beta-blockers remain a standard of care following AMI, however the 
evidence was based on studies performed before the era of reperfusion [50]. In a recent large-
scale observational study, a benefit with beta-blockade in post-AMI patients was shown, but 
only among patients with LV dysfunction [51].  
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Specific aspects for the selection: This QI was already in the 2017 ESC-ACVC list.  The exact 
type of beta-blocker indicated for patients with LV systolic dysfunction was not specified for 
the QI, given the complexity of the measure. 
 
Domain 6: Patient satisfaction 
 Feedback regarding the patient’s experience and systematic assessment of health-
related quality of life  
Clinical relevance: The concept of “patient-centered care” is based on focusing care on the 
patient rather than on the disease. In this approach, patients are actively involved in their own 
care, congruent with the principle of shared-decision making. Patient-Reported Outcomes 
(PRO, which can be seen as an assessment of the perceived level of impairment, disability and 
quality of life) and Patient-Reported Experience (PRE, which gather information on the care) 
[52] can be considered as QIs. To this end, PRO and PRE can be measured through patient 
satisfaction questionnaires [53]. In the setting of AMI, patient satisfaction PRO and PRE are 
associated with other indices of quality of care [54, 55]. 
Specific aspects for selection: This QI was already included in the 2017 ESC-ACVC QI list, 
but only partial assessment has been reported, except for ‘referral to rehabilitation 
programmes’ and ‘pain control’. The use of a health-related quality of life questionnaire at 
discharge is reported in the long-tErm follow-up of antithrombotic management patterns In 
acute CORonary syndrome patients (EPICOR) and the Evaluation of the Methods and 
Management of Acute Coronary Events (EMMACE)-3 and -4 registries [8]. The Study Group 
has defined the main QI as a 4-item composite indicator including referral to a rehabilitation 
programme, patient information about the disease, treatment and pain control. The secondary 
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QI is the assessment of the health-related quality of life in all patients using a validated 
instrument. 
 
 Discharge letter sent to the patient  
Clinical relevance: Copying the hospital discharge letter to the patient is an essential part of 
communication. The UK Academy of Medical Royal Colleges has published guidance on this 
topic, considering that excellent written communication is essential to good quality of care 
and that the letter would be better addressed to the patient and not to the corresponding 
physician (“Write to, not about”) [56]. This practice of writing to the patient, compared with 
writing to the clinician, increases patient satisfaction, improves both the doctor-patient 
relationship and trust, and reduces anxiety [57].  
Specific aspects for selection: To date, no similar QI or PM has been defined, but it appears to 
be feasible even if this currently remains undetermined. 
 
Domain 7: Outcome and Composite QI  
 Outcomes QI:  30-day mortality rate adjusted for a validated risk score is unchanged. 
Clinical relevance: All-cause mortality is a self-evident assessment of quality of care and the 
most easily interpretable, objective and unambiguous indicator. While the accuracy of 
mortality as a direct measure of quality of care is controversial [58], the association between 
the ESC ACVC composite QI and the risk-adjusted outcomes is important.  
Specific aspects for the selection: All-cause mortality is easy to assess and this measure 
provides essential information at broad-level (i.e. region-, country- or continent-levels). At 
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centre-level, the interpretation may be more challenging and less generalizable, depending on 
the size of the denominator. 
 
 Composite QI: 
Composite quality indicators (CQI) summarize information from different domains into a 
single measure. Thus, it is possible to expand the scope of the measure by including a broad 
range of individual indicators, to provide a single metric that enables temporal comparisons, 
classification of centres and demonstration of the association between the CQI and outcomes, 
a way of reassuring clinicians about the validity of process instead of clinical outcome 
assessment [13].  
Clinical relevance: By reducing the information from all domains into a single CQI, the areas 
for specific improvement may be obscured. Among the different types of composites, the 
opportunity-based and the all-or-none are the most frequently recommended for the quality of 
care assessment [59, 60]. Since the two methods, while associated [61], provide different 
approaches, both types of CQI have been maintained in the updated version. The main CQI is 
an opportunity-based score, where all domains are represented and have the same weight 
(except in patients with LVEF <40% in whom two additional items are required, giving more 
weight to the secondary prevention domain). This design has the advantage of increasing the 
number of items, which may vary according to the patient characteristics and the database 
used. The secondary CQI has an all-or-none design with only three individual QIs, but all 
three are deemed clinically relevant: the timely reperfusion or invasive strategy, the 
prescription of the “appropriate” P2Y12 inhibition and high-intensity statins. With this CQI, 
only patients who received all three processes are considered as a success and therefore, this 
method best reflects the patient’s interest and tracks excellence.  
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Specific aspects for the selection: In the previous experience of assessment of the 2017 ESC 
ACVC QIs, the opportunity-based CQI was reported in most cases and, after transformation 
into categories, was associated with mortality [2, 3, 5, 7, 8]. The Study Group decided that the 
opportunity-based CQI should contain one item per domain, namely the most adequate to 
capture quality, despite the challenges for assessment, and considering that this was more an 
issue related to the design of current registries than the definition of the CQI. 
 
 
Comparison with previous Quality Metrics definitions and future 
developments 
The comparison of QI selection between the ESC ACVC 2020 and ESC-ACCA 2017, the 
American College of Cardiology (ACC) and AHA 2017 and Canadian Cardiovascular Society 
(CCS) 2007 is presented in Table 1. 
 Centre organisation: compared to the 2017 selection, the QI on availability of hs-cTn in 
the centre is new.  
 Reperfusion/invasive strategy: the number of QIs has been reduced and the indicators 
related to the time for reperfusion have been aligned with the 2017 ESC GL and 
simplified as compared to the 2017 definition. As compared to the ACC/AHA measure 
set, the starting time is the initial diagnosis of STEMI (versus first medical contact for 
ACC/AHA) and the thresholds are different: <60 min to wire crossing the lesion for 
patients presenting at a primary PCI hospital, or <90 min for patients diagnosed either in a 
non-PCI hospital or in the out-of-hospital setting who were then transferred to a PCI-
capable centre, and < 10min in case of reperfusion with fibrinolysis. The radial access QI 
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is new, and has not been presented in other selections. The reduction of the time to 
invasive approach to 24h in NSTEMI is in line with comparable PM from the ACC/AHA.  
 Risk assessment: The main change is the simplification of the overall risk assessment, 
without specifying specific risk scores. The assessment of LDL-c has been added as a 
Main QI. The ESC Guidelines recommend this measure because available evidence 
supports the addition of ezetimibe and PCSK9 inhibitors on top of high-intensity statins in 
selected patients.  
 Antithrombotic treatment during hospitalization: the prescription of “adequate P2Y12 
inhibition”, already in the 2017 list, has been confirmed, despite the complexity of the 
assessment. The selection of an “adequate” P2Y12 inhibitor is also in the ACC/AHA PM 
list with two different definitions, both focusing on the safety side, without considering 
the potential benefit of using a more potent P2Y12 inhibitor in eligible patients. The use of 
fondaparinux (for NSTE-ACS in the ACVC 2017 selection) has been replaced by the use 
of a parenteral agent at admission. The mention of the duration of DAPT in the discharge 
letter is a new indicator, never seen in previous selections. As in 2017, aspirin at 
admission and at discharge are not included in the list of QIs, reflecting the fact that 
although this treatment is of paramount importance, the Study Group considers it to be 
widely applied, with limited room for improvement [30]. 
 Secondary Prevention: There has been no change to this section, compared to the 2017 
selection. The prescription of high-intensity statins at discharge was also adopted by 
ACC/AHA, while aspirin at discharge (and at admission) is considered to be “topped out” 
and not included in the ESC ACVC list. 
 Patient satisfaction: With the exception of cardiac rehabilitation, no comparable 
indicators have been defined by the ACC/AHA or CCS. The Study Group consider these 
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QI to be important, and there is a compelling need to include the necessary variables in 
future registries to render assessment possible.  
 Mortality: Risk-adjusted 30-day all-cause mortality has been maintained in the updated QI 
list, despite significant limitations for interpretation. In contrast, no outcome measure has 
been selected by ACC/AHA, because the outcomes are only partially dependent on the 
quality of care, risk adjustment is challenging and, used as PM and not a QI, inclusion of 
outcome measures could have potentially negative consequences [12]. 
 
Perspectives 
The first set of QIs was developed to improve quality through self-assessment. This has been 
possible in different countries, not carried out by health agencies or insurance companies, but 
by cardiologists themselves at low cost through existing registries. To facilitate such use of 
QIs, the Study Group considered the results of these assessments in revising the QIs. Thus, 
some QIs that were found to be challenging to report have been retired or modified. 
Conversely, despite not being measured in all registries, certain QIs have been maintained, 
considering that they capture important aspects of quality care. The next step will be the 
standardization of the main registries in Europe in order to include the specific variables 
needed for quality assessment according to the revised set of QIs. In most existing registries 
and surveys, this would correspond to the addition of a limited number of variables, which 
should be reliable and straightforward to assess. 
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Figure Legend 
Figure 1: Main and secondary Quality Indicators for each domain. Timely reperfusion is 
defined as time from STEMI diagnosis to (1) infarct-related artery wire crossing : <60 min for 
patients presenting at a primary PCI hospital,  or (2) <90 min for patients diagnosed either in a 
non-PCI hospital or in the out-of-hospital setting, or (3) injection of the bolus of fibrinolysis < 
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Table 1: Quality metrics selected by ESC-ACVC 2020, ESC ACCA 2017, 2020, 
ACC/AHA 2017, and CCS 2007.  
In bold, the Main QIs in 2020. Green cases for quality metric with comparable definition as 
ESC ACVC 2020; in orange quality metric selected items with a different definition, in white, 
no corresponding quality metric. In red, withdrawn indicators 











Network     
Availability of hs-cTn     
Pre-hospital interpretation of 
ECG 
    
Quality registry programme     
Systematic assessment of times to 
reperfusion 





STEMI with reperfusion     
Timely reperfusion by PCI     
Time for fibrinolytic therapy     
Door to needle time     
Door in Door out time     
Time to PCI transferred patient     
Invasive strategy <24h     
Radial access     




LVEF assessment     
LDL-c assessment     
Risk assessment with a validated 
score 
    
Antithromboti
cs 
Adequate P2Y12     
Aspirin admission     
Parenteral anticoagulation     
DAPT at discharge     
Mention about DAPT duration     
Secondary 
Prevention 
High-intensity statins     
Aspirin discharge     
ACEI/ARB if LVEF<40%     
Aldosterone antagonist at discharge     
Beta-blockers if LVEF<40%     
Patient 
satisfaction 
Feedback     
Cardiac rehabilitation     
Smoking cessation advice     
Quality of life     
Discharge letter     
Cardiac arrest Immediate angiography     
Hypothermia     
Composite 
Indicator 
Opportunity-based     
All or none     






















Table S1. Assessment of the 2017 ESC ACVC QIs in different international patient registries. Rates of QIs reported by domains and by cohorts  
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Table S2: Definition of the Main and Secondary Quality Indicators for each of the seven domains of care 
Domain 1 : Centre organisation Assessment GL Class  ACP Measure criteria 
Main (1) The centre should be part of a network 
organisation with written protocols for rapid 
and efficient management  
Numerator: centres 
participating in a network for 
management of STEMI and 
NSTEMI patients with written 
protocols.  
 
I B Importance: high impact 
Appropriate care: underuse 
Evidence base: recommended, high level of 
evidence 
Measure specification: measure reliable, no 
denominator (by center) 
Measure feasibility: under physicians’ control, 
usable, data collection feasible, low 
complexity, time dependent variable 
Main (2):  
 
Hospital use of hs-cTn. 
 
Numerator: Availability of hs-
cTn assay in the center 
IC Importance: high impact 
Appropriate care: underuse 
Evidence base: recommended, high level of 
evidence 
Measure specification: measure reliable, no 
denominator (by center) 
Measure feasibility: under physicians’ control, 
usable, data collection feasible, low 
complexity, time dependent variable 
Main (3) Pre-hospital interpretation of ECG for  
1) diagnosis,  
2) decision for immediate transfer to a 
centre with catheterisation laboratory 
facilities, and  
3) pre-hospital activation of the 
catheterisation laboratory 
Numerator: Availability of 
system for pre-hospital ECG 
interpretation and transfer 
decisions. 
 
IC Importance: high impact 
Appropriate care: underuse 
Evidence base: recommended, low level of 
evidence 
Measure specification: measure reliable, no 
denominator (by center) 
Measure feasibility: under physicians’ control, 
usable, data collection feasible, moderate 
complexity, time dependent variable 
Secondary (1) The centre should participate in a regular 
registry or programme for quality 
Numerator: Centres 
participating regularly in local, 
IC  Importance: high impact 
Appropriate care: underuse 
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assessment regional, national or 
international quality registry  
Evidence base: recommended, low level of 
evidence 
Measure specification: measure reliable, no 
denominator (for the center) 
Measure feasibility: under physicians’ control, 
usable, data collection feasible, low 
complexity, time dependent variable 
Secondary (2): Routine assessment of relevant times for the 
reperfusion process in STEMI patients (i.e. 
times from ‘call to first medical contact’, 
‘first medical contact to arrival at PCI centre, 
arrival at PCI centre to arterial access) 
Numerator: Routine monitoring 
of relevant reperfusion times in 
primary PCI programs 
 
I C Importance: high impact 
Appropriate care: underuse 
Evidence base: recommended, low level of 
evidence 
Measure specification: uncertain reliability, 
no denominator (for the center) 
Measure feasibility: under physicians’ control, 
usable, data collection feasible, high 
complexity, time dependent variable 
 
 
Domain 2 : Reperfusion/Invasive strategy Assessment GL Class  ACP Measure criteria 
Main (1)  Proportion of patients with STEMI 
reperfused among those eligible (onset of 
symptoms to diagnosis <12 h).  
Numerator: Number of eligible 
patients with STEMI <12 hours 
undergoing reperfusion 
Denominator: number of 
patients with STEMI eligible for 
reperfusion and without 
contraindications  
I A Importance: high impact 
Appropriate care: underuse 
Evidence base: recommended, high level of 
evidence 
Measure specification: measure reliable, 
numerator-denominator clearly defined 
Measure feasibility: under physicians’ control, 
usable, high burden of patients (STEMI), data 
collection feasible, low complexity, variable 
recorded in most current registries.   
Main (2)  Proportion of patients with STEMI who 
receive timely reperfusion. Timely is defined 
Numerator: number of patients 
with STEMI undergoing timely 
I A Importance: high impact 
Appropriate care: underuse 
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as: 
1) For patients presenting at primary PCI 
hospitals: <60 min from initial STEMI 
diagnosis to infarct-related artery wire 
crossing  
2) For patients diagnosed either in a non-
PCI hospital or in the out-of-hospital 
setting and then transferred to a PCI-
capable center: <90 min from initial STEMI 
diagnosis to infarct-related artery wire 
crossing  
3) For patients treated with fibrinolysis, 
initiation of fibrinolysis within 10 minutes 
after STEMI diagnosis 
 
reperfusion with Primary PCI or 
fibrinolysis 
Denominator: all patients with 
STEMI eligible for reperfusion  
Evidence base: recommended, high level of 
evidence 
Measure specification: uncertain reliability, 
numerator-denominator clearly defined 
Measure feasibility: under physicians’ control, 
usable, high burden of patients (STEMI), data 
collection feasible, low complexity, but 
variables not recorded in all current registries. 
Main (3)  Rate of NSTEMI patients who receive 
invasive coronary angiography within 24h of 
their diagnosis 
Numerator: number of NSTEMI 
patients who receive invasive 
coronary angiography within 
24h of their diagnosis. 





Importance: high impact 
Appropriate care: underuse 
Evidence base: recommended, high level of 
evidence 
Measure specification: measure reliable, 
numerator-denominator clearly defined 
Measure feasibility: under physicians’ control, 
usable, high burden of patients (NSTEMI), data 
collection feasible, low complexity, variable 
recorded in most current registries.   
Main (4):  Use of radial access in case of invasive 
strategy 
Numerator: number of patients 
who receive invasive coronary 
angiography via radial access. 
Denominator: number of 
patients who receive invasive 
coronary angiography without 
overriding procedural 
considerations against the use 
I B 
 
Importance: high impact 
Appropriate care: underuse 
Evidence base: recommended, high level of 
evidence 
Measure specification: measure reliable, 
numerator-denominator clearly defined 
Measure feasibility: under physicians’ control, 
usable, high burden of patients (STEMI), data 
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of radial access collection feasible, low complexity, variable 
recorded in most current registries.   
Secondary (1) The time between the initial STEMI diagnosis 
and arterial access (absolute value) for 
primary PCI. 
Numerator median time 
between initial STEMI diagnosis 
and arterial access among 
STEMI patients undergoing 
reperfusion  
 
I C Importance: high impact 
Appropriate care: underuse 
Evidence base: recommended, high level of 
evidence 
Measure specification: uncertain reliability, 
numerator-denominator clearly defined 
Measure feasibility: under physicians’ control, 
usable, high burden of patients (STEMI), data 
collection feasible, low complexity, variable 
recorded in most current registries.   
 
 
Domain 3 : In-hospital risk assessment Assessment GL Class  ACP measure criteria 
Main (1) The proportion of patients who have an 
assessment of LVEF before hospital 
discharge (LVEF should be assessed and the 
numerical value recorded for all patients). 
Numerator: number of patients 
who have their LVEF measured 
before hospital discharge 
Denominator: Total number of 
patients with a diagnosis of AMI 
I C 
 
Importance: high impact 
Appropriate care: underuse 
Evidence base: recommended, low level of 
evidence 
Measure specification: measure reliable, 
numerator-denominator clearly defined 
Measure feasibility: under physicians’ control, 
usable, high burden of patients, data 
collection feasible, low complexity, variable 
recorded in most current registries.   
Main (2) LDL-Cholesterol assessment should be 
performed during hospitalization 
Numerator: number of patients 
who have their LDL-cholesterol 
measured during 
hospitalization. 
Denominator: Total number of 
patients with a diagnosis of AMI 
I C Importance: meaningful clinical impact 
Appropriate care: underuse 
Evidence base: high level of evidence 
Measure specification: measure reliable, 
numerator-denominator clearly defined 
Measure feasibility: under physicians’ control, 
usable, high burden of patients, data 
collection feasible, low complexity, variable 
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recorded in most current registries.   
Secondary (1)  
 
Ischemic and haemorragic risk assessment 
should be performed using a validated risk 
score. 
Numerator: number of patients 
who have been stratified 
according to a validated risk 
score 
Denominator: Total number of 
patients with a diagnosis of AMI 
IIa C 
 
Importance: performance gap 
Appropriate care: underuse 
Evidence base: recommended, low level of 
evidence 
Measure specification: measure reliable, 
numerator-denominator clearly defined 
Measure feasibility: uncertain, usable, high 
burden of patients, data collection feasible, 
low complexity, but variable not recorded in 




Domain 4: Anti-thrombotic treatment during hospitalisation Assessment GL Class  ESC-ACCA QI 2017 definition 
Main (1) Proportion of patients with “adequate P2Y12 
inhibition” defined as: (number of patients 
discharged with prasugrel, ticagrelor, or 
clopidogrel)/(patients eligible). 
Eligible is defined as follows: 
 For ticagrelor: AMI patients without 
previous haemorrhagic stroke, high 
bleeding risk, fibrinolysis or oral 
anticoagulation. 
 For prasugrel: PCI-treated AMI patients 
without previous haemorrhagic or 
ischaemic stroke, high bleeding risk 
(patients ⩾75 years and/or <60 kg body 
weight are also considered as high 
bleeding risk features), fibrinolysis or 
oral anticoagulation. 
 For clopidogrel: no indication for 
prasugrel or ticagrelor and no high 
bleeding risk. 
Numerator: Number of patients 
prescribed adequate P2Y12 
inhibitor at the time of hospital 
discharge.  
Denominator: Number of 
patients discharged who have 
an indication for dual 
antiplatelet therapy  
 I A 
. 
Importance: high impact 
Appropriate care: underuse and overuse 
Evidence base: recommended, high level of 
evidence 
Measure specification: measure reliable, 
numerator-denominator complex to define 
Measure feasibility: under physicians’ control, 
usable, high burden of patients, data 
collection feasible, moderate complexity, 
variable recorded in most current registries. 
Main (2) Parenteral anticoagulant at admission Numerator: number of patients 
treated with one parenteral 
anticoagulant until coronary 
revascularisation 
Denominator: All patients not 
treated with VKA 
I A Importance: high impact 
Appropriate care: underuse and overuse 
Evidence base: recommended, high level of 
evidence 
Measure specification: measure reliable, 
numerator-denominator easy to define 
Measure feasibility: under physicians’ control, 
usable, high burden of patients, data 
collection feasible, low complexity, variable 
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recorded in most current registries.   
Secondary (1)  
 
Patients discharged on dual antiplatelet 
therapy 
Numerator: number of patients 
prescribed dual antiplatelet 
therapy at the time of hospital 
discharge. 
Denominator: patients alive at 
the time of hospital discharge 
who have an indication for dual 




Importance: high impact 
Appropriate care: underuse  
Evidence base: recommended, high level of 
evidence 
Measure specification: measure reliable, 
numerator-denominator easy to define 
(contra-indications not recorded in all 
registries). 
Measure feasibility: under physicians’ control, 
usable, high burden of patients, data 
collection feasible, moderate complexity, 
variable recorded in most current registries.   
Secondary (2) Mention the duration of the dual 
antiplatelet therapy in the discharge letter 
Numerator :  number of 
patients for whom the duration 
of the dual antiplatelet therapy 
is specified in the discharge 
document  
Denominator: number of 
patients prescribed dual 
antiplatelet therapy at the time 
of hospital discharge  
No Importance: high impact 
Appropriate care: underuse  
Evidence base: no recommendation, low level 
of evidence. 
Measure specification: measure reliable, 
numerator-denominator complex to define 
Measure feasibility: under physicians’ control, 
usable, high burden of patients, data 
collection feasible, low complexity, but 
variable not recorded in current registries.   
 
 
Domain 5 : Secondary prevention discharge treatments Assessment GL Class  ACP Measure criteria 
Main   
 
Proportion of patients discharged from 
hospital on high intensity statins (defined as 
atorvastatin ⩾40 mg or rosuvastatin ⩾20 
mg) unless contraindicated 
Numerator: number of patients 
who receive high intensity statin 
therapy at the time of hospital 
discharge. 
Denominator: number of 
I A 
 
Importance: high impact 
Appropriate care: underuse  
Evidence base: recommended, high level of 
evidence 
Measure specification: measure reliable, 
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patients alive at the time of 
hospital discharge and without 
contraindications, refusal, side 
effects or history of intolerance 
to high-intensity statin therapy. 
numerator-denominator complex to define 
(intolerance not recorded in all registries) 
Measure feasibility: under physicians’ control, 
usable, high burden of patients, data 
collection feasible, moderate complexity, but 
variable not recorded in most current 
registries.   
Secondary (1) 
 
Proportion of patients with LVEF <40% who 
are discharged from hospital on ACEI (or 
ARBs if intolerant of ACEI). 
Numerator: number of patients 
with a LVEF <40%, prescribed 
ACEI/ARB at the time of hospital 
discharge. 
Denominator: number of 
patients with LVEF <40% and 
alive at the time of hospital 
discharge who are eligible for 
ACEI/ARBs (no severe renal 
impairment, 
hyperkalaemia, other contra-
indication, refusal, side 
effects, or allergy). 
I A 
  
Importance: high impact 
Appropriate care: underuse  
Evidence base: recommended, high level of 
evidence 
Measure specification: measure reliable, 
numerator-denominator easy to define 
(contra-indication not recorded in all 
registries) 
Measure feasibility: under physicians’ control, 
usable, low burden of patients, data collection 
feasible, moderate complexity, variable 
recorded in most current registries.   
Secondary (2) 
 
Proportion of patients with LVEF <40% who 
are discharged from hospital on beta-
blockers 
Numerator: number of patients 
with LVEF <40%, prescribed 
beta-blockers at the time of 
hospital discharge. 
Denominator: number of 
patients with LVEF <40%, and 
alive at the time of hospital 




Importance: high impact 
Appropriate care: underuse  
Evidence base: recommended, high level of 
evidence 
Measure specification: measure reliable, 
numerator-denominator easy to define 
(contra-indication not recorded in all 
registries) 
Measure feasibility: under physicians’ control, 
usable, low burden of patients, data collection 
feasible, moderate complexity, variable 




Domain 6 : Patient satisfaction Assessment GL Class  ACP Measure criteria 
Main  
 
Feedback regarding the patient’s experience 
systematically collected in an organized way 
from all patients. It should include the 
following points:  
(1) Recommendation to attend an 
educational program (rehabilitation, 
smoking cessation, weight control and diet 
counselling). 
(2) Explanations provided by doctors and 
nurses (about the coronary disease, the 
benefit/risk of the discharge treatment, and 
medical follow-up). 
(3) Discharge information regarding what to 
do in case of recurrence of symptoms and 
timing of visit. 
(4) Pain control. 
Numerator: number of patients 
alive at the time of discharge 
from hospital from whom 
feedback is collected 
Denominator: number of 
patients discharged from 
hospital alive 
No  Importance: performance gap 
Appropriate care: underuse  
Evidence base: not recommended, low level 
of evidence 
Measure specification: measure complex, 
numerator-denominator easy to defined 
Measure feasibility: out of physicians’ control, 
usable, high burden of patients, data 
collection feasible, high complexity, but 
variable not recorded in current registries. 
Secondary (1) Systematic assessment of health-related 
quality of life in all patients using a validated 
instrument. 
Numerator: number of patients 
with MI alive at the time of 
hospital discharge who have 
their health-related quality of 
life assessed during 
hospitalization using a validated 
instrument 
Denominator: number of 
patients with MI discharged 
from hospital 
No Importance: performance gap 
Appropriate care: underuse  
Evidence base: not recommended, low level 
of evidence 
Measure specification: measure complex, 
numerator-denominator easy to defined 
Measure feasibility: out of physicians’ control, 
usable, high burden of patients, data 
collection feasible, low complexity but 
variable not recorded in current registries. 
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Secondary(2) The discharge letter should be sent to the 
patient 
Numerator: number of patients 
with MI discharged alive who 
were the recipient of the 
discharge letter  
Denominator: number of 




Importance: performance gap 
Appropriate care: underuse  
Evidence base: not recommended, low level 
of evidence 
Measure specification: feasible, numerator-
denominator easy to defined 
Measure feasibility: under physicians’ control, 
usable, high burden of patients, data 
collection feasible, low complexity but 
variable not recorded in current registries.   
 
Domain 7: COMPOSITE INDICATORS and OUTCOMES 
 




Opportunity based composite QI (all indicators are 
weighted equally) based on: 
Calculated on 6 individual QIs in patients with 
LVEF≥40%:   
1) The centre should participate in a regular registry or 
program for quality assessment. 
2)-STEMI): proportion of patients with STEMI 
reperfused among those eligible (onset of symptoms 
to initial diagnosis <12 h). 
2)-NSTEMI): proportion of patients with NSTEMI who 
receive invasive coronary angiography within 24h of 
their initial diagnosis. 
3) Assessment of LVEF before hospital discharge. 
4) Discharge on adequate P2Y12 inhibition. 
Numerator: all patients 
with MI discharged from 
hospital alive: sum of 
points (one point for each 
individual indicator).  
Denominator: all patients 
with MI discharged from 
hospital alive: sum of 
points (one point for each 
applicable indicator, 





Importance: meaningful clinical impact 
Appropriate care: underuse  
Evidence base: high level of evidence 
Measure specification: feasible, numerator-
denominator easy to defined 
Measure feasibility: under physicians’ control, 
usable, high burden of patients, data 
collection feasible, high complexity but 
variables recorded in most current registries.  
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5) Discharge on high-intensity statins. 
6) Feedback regarding the patient’s experience 
systematically collected  
Additional items in patients with clinical evidence of 
heart failure or LVEF<40%. 
7) LVEF <40%: discharged on ACEI/ARB. 
8) LVEF <40%: discharged on beta-blockers  
 
Composite QI (CQI) 
 
Assessment GL Class  ESC-ACCA QI 2017 definition 
Secondary:  
All-or-none  
All or None composite QI based on 3 or 5 
components,  
1-STEMI: Patients with STEMI who receive timely 
reperfusion, among those eligible  
1- NSTEMI: Patients with NSTEMI with invasive 
coronary angiography within 24h of their initial 
diagnosis 
2) Discharge on adequate P2Y12 inhibition 
3) Discharged on high-intensity statins. 
Additional items in patients with clinical evidence 
of heart failure or LVEF<40%. 
4) Discharge on beta-blockers. 
5) Discharge on ACEI or ARB. 
Numerator: all patients 
with MI discharged from 
hospital alive: sum of 
points (one point for each 
individual indicator).  
Denominator: all patients 
with MI discharged from 
hospital alive: sum of 
points (one point for each 
applicable indicator, 
according to patient and 
centre characteristics) 
 
 Importance: meaningful clinical impact 
Appropriate care: underuse  
Evidence base: high level of evidence 
Measure specification: feasible, numerator-
denominator easy to defined 
Measure feasibility: under physicians’ control, 
usable, high burden of patients, data 
collection feasible high complexity, variables 
recorded in most current registries. 
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Outcome QI Definition GL Class  ACP Measure criteria 
Main Risk adjusted  30-day mortality rate  Numerator all 
patients with MI 
who died within the 
first 30 days after 
admission 
Denominator all 
patients with a 
diagnosis of AMI 
No  Importance: meaningful clinical impact 
Appropriate care: underuse  
Evidence base: high level of evidence 
Measure specification: feasible, numerator-
denominator easy to defined 
Measure feasibility: under physicians’ control, 
usable, high burden of patients, data 
collection feasible, low complexity, variable 
recorded in most current registries. 
 
ACP Measure criteria: criteria to assess the validity of performance measures as defined by the American College of Physicians. STEMI= ST segment elevation 
acute myocardial infarction; NSTEMI=Non-ST elevation acute myocardial infarction; GL=guidelines; NSTEMI=Non-ST elevation myocardial infarction; 
IQR=interquartile range; LVEF=left ventricular ejection fraction; LDL=low-density lipoprotein; DAPT=dual antiplatelet therapy; ACEI=angiotensin-converting-
enzyme inhibitors; ARB=angiotensin-receptor blockers; CCS=chronic coronary syndrome; CKD= chronic kidney disease; CQI=composite quality indicator 
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